GAMBARAN KADAR KREATININ PADA PASIEN HIPERTENSI SEBAGAI INDIKATOR FUNGSI GINJAL DI RSUD TOTO KABILA
DOI:
https://doi.org/10.47918/gxb21n74Keywords:
hipertensi, kadar kreatinin, fungsi ginjal, kreatinin serum, RSUD Toto Kabila.Abstract
Penelitian ini bertujuan untuk mengetahui gambaran kadar kreatinin pada pasien hipertensi sebagai indikator fungsi ginjal di RSUD Toto Kabila. Penelitian ini menggunakan desain deskriptif observasional dengan pendekatan cross-sectional. Sampel penelitian berjumlah 15 pasien hipertensi yang memenuhi kriteria inklusi dan dipilih menggunakan teknik purposive sampling. Pemeriksaan kadar kreatinin serum dilakukan di Laboratorium RSUD Toto Kabila menggunakan Automatic Chemistry Analyzer Mindray BS-380, sedangkan data dianalisis secara univariat dan disajikan dalam bentuk distribusi frekuensi, persentase, serta deskripsi karakteristik responden. Hasil penelitian menunjukkan bahwa 13 responden (86,7%) memiliki kadar kreatinin dalam kategori normal (0,5–1,3 mg/dL), sedangkan 2 responden (13,3%) memiliki kadar kreatinin abnormal (>1,3 mg/dL). Mayoritas responden berjenis kelamin perempuan (73,3%) dan berada pada kelompok usia 45–59 tahun. Nilai kadar kreatinin berkisar antara 0,54 mg/dL hingga 25,07 mg/dL, dengan dua responden menunjukkan peningkatan kadar kreatinin yang mengindikasikan adanya penurunan fungsi ginjal. Disimpulkan bahwa sebagian besar pasien hipertensi di RSUD Toto Kabila masih memiliki kadar kreatinin dalam batas normal, namun sebagian kecil telah mengalami peningkatan kadar kreatinin yang berpotensi menunjukkan gangguan fungsi ginjal. Oleh karena itu, pemeriksaan kreatinin serum secara berkala perlu dilakukan sebagai upaya deteksi dini dan pemantauan fungsi ginjal pada pasien hipertensi.
Downloads
References
[1] S. Z. Fadem, “Hypertension and Kidney Disease,” in Staying Healthy with Kidney Disease: A Complete Guide for Patients, Department of Medicine, Division of Nephrology, Baylor College of Medicine, Houston, TX, United States: Springer Science+Business Media, 2022, pp. 35–41. doi: 10.1007/978-3-030-93528-3_5.
[2] Y. He et al., “Global burden of chronic kidney disease due to hypertension (1990–2021): a systematic analysis of epidemiological trends, risk factors, and projections to 2036 from the GBD 2021 study,” BMC Nephrol., vol. 26, no. 1, 2025, doi: 10.1186/s12882-025-04386-8.
[3] Y. Ren, Z. Wang, and Q. Wang, “The trend of hypertension-related chronic kidney disease from 1990 to 2019 and its predictions over 25 years: an analysis of the Global Burden of Disease Study 2019,” Int. Urol. Nephrol., vol. 56, no. 2, pp. 707–718, 2024, doi: 10.1007/s11255-023-03707-w.
[4] Y. Bu et al., “The Burden of Hypertension-Related Chronic Kidney Disease — China, 2010–2019,” China CDC Wkly., vol. 6, no. 14, pp. 282–288, 2024, doi: 10.46234/ccdcw2024.055.
[5] R. D. Hutapea, Y. Widaningsih, F. Mangarengi, and D. Muhadi, “Analysis of Urea, Creatinine, and Platelet Indices in Hypertensive Patients,” Indones. J. Clin. Pathol. Med. Lab., vol. 27, no. 2, pp. 117–121, 2021, doi: 10.24293/ijcpml.v27i2.1666.
[6] K. Kashani, M. H. Rosner, and M. Ostermann, “Creatinine: From physiology to clinical application,” Eur. J. Intern. Med., vol. 72, pp. 9–14, 2020, doi: 10.1016/j.ejim.2019.10.025.
[7] M. Ávila, M. G. Mora Sánchez, A. S. Bernal Amador, and R. Paniagua, “The Metabolism of Creatinine and Its Usefulness to Evaluate Kidney Function and Body Composition in Clinical Practice,” Biomolecules, vol. 15, no. 1, 2025, doi: 10.3390/biom15010041.
[8] R. Li, L. Wang, H. Qian, F. Zhang, B. Dong, and W. Shu, “Research progress of creatinine as biomarkers in disease diagnosis and drug evaluation,” Drug Eval. Res., vol. 44, no. 9, pp. 2007–2012, 2021, doi: 10.7501/j.issn.1674-6376.2021.09.030.
[9] S. N. Prabhu, S. C. Mukhopadhyay, and G. Liu, “Sensors and Techniques for Creatinine Detection: A Review,” IEEE Sens. J., vol. 22, no. 12, pp. 11427–11438, 2022, doi: 10.1109/JSEN.2022.3174818.
[10] I. Wu and C. R. Parikh, “Screening for kidney diseases: Older measures versus novel biomarkers,” Clin. J. Am. Soc. Nephrol., vol. 3, no. 6, pp. 1895–1901, 2008, doi: 10.2215/CJN.02030408.
[11] G. V Galen, E. Olsen, and N. Siwinska, “Biomarkers of Kidney Disease in Horses: A Review of the Current Literature,” Animals, vol. 12, no. 19, 2022, doi: 10.3390/ani12192678.
[12] A. Suresh, N. Muninathan, S. Sampath, S. Devanesan, M. S. AlSalhi, and D. Manoj, “Role of traditional and new biomarkers in the assessment of chronic kidney diseases: a comprehensive analysis of the biochemical, molecular and clinical dimensions,” Mol. Biol. Rep., vol. 52, no. 1, 2025, doi: 10.1007/s11033-025-10498-z.
[13] J. Zhu, K. Wen, and H. He, “Diagnostic value of urinary protein and creatinine in combination with renal ultrasound examination in early renal damage of patients with hypertension,” Pakistan J. Med. Sci., vol. 31, no. 4, pp. 899–902, 2015, doi: 10.12669/pjms.314.7513.
[14] X. Ji, “Hypertensive Kidney Disease,” in Chronic Kidney Disease: Diagnosis and Treatment, Division of Nephrology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China: Springer Singapore, 2019, pp. 45–56. doi: 10.1007/978-981-32-9131-7_4.
[15] S. A. Hebert and H. N. Ibrahim, “Hypertension Management in Patients with Chronic Kidney Disease,” Methodist Debakey Cardiovasc. J., vol. 18, no. 4, pp. 41–49, 2022, doi: 10.14797/mdcvj.1119.
[16] F. T. Hammad et al., “The Effect of Hypertension on the Recovery of Renal Dysfunction following Reversal of Unilateral Ureteral Obstruction in the Rat,” Int. J. Mol. Sci., vol. 24, no. 8, 2023, doi: 10.3390/ijms24087365.
[17] C. Wang, Z. Wang, and W. Zhang, “The potential role of complement alternative pathway activation in hypertensive renal damage,” Exp. Biol. Med., vol. 247, no. 9, pp. 797–804, 2022, doi: 10.1177/15353702221091986.
[18] R. W. Major, “Clinical assessment of kidney function and prognosis in adults,” Med. (United Kingdom), vol. 51, no. 2, pp. 98–101, 2023, doi: 10.1016/j.mpmed.2022.11.009.
[19] S.-V. Giannelli, C.-E. Graf, D. Zekry, and F.-R. Herrmann, “Kidney function estimation in older adults: Comparison of different methods and clinical implications,” NPG Neurol. - Psychiatr. - Geriatr., vol. 13, no. 75, pp. 166–171, 2013, doi: 10.1016/j.npg.2012.10.004.
[20] G. Bezerra da Silva Junior, E. Barros, E. D. F. Daher, and F. V Veronese, “Renal function evaluation in tropical diseases,” in Tropical Nephrology, School of Medicine, University of Fortaleza, Fortaleza, Ceara, Brazil: Springer International Publishing, 2020, pp. 17–26. doi: 10.1007/978-3-030-44500-3_2.
[21] G. Bezerra da Silva Junior et al., “Kidney Function Evaluation in Tropical Diseases,” in Sustainable Development Goals Series, vol. Part F915, School of Medicine, Universidade de Fortaleza, Ceara, Fortaleza, Brazil: Springer, 2025, pp. 351–357. doi: 10.1007/978-3-031-94777-3_33.
[22] J. Malyszko et al., “How to assess kidney function in oncology patients,” Kidney Int., vol. 97, no. 5, pp. 894–903, 2020, doi: 10.1016/j.kint.2019.12.023.
[23] A. Davenport, E. Cholongitas, E. Xirouchakis, and A. K. Burroughs, “Pitfalls in assessing renal function in patients with cirrhosis-potential inequity for access to treatment of hepatorenal failure and liver transplantation,” Nephrol. Dial. Transplant., vol. 26, no. 9, pp. 2735–2742, 2011, doi: 10.1093/ndt/gfr354.
[24] H.-W. Moon and M. Hur, “NGAL vs. creatinine,” in Neutrophil Gelatinase-Associated Lipocalin: From Laboratory to Clinical Utility, Department of Laboratory Medicine, Konkuk University School of Medicine, Seoul, South Korea: Nova Science Publishers, Inc., 2014, pp. 87–100. [Online]. Available: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84956975419&partnerID=40&md5=7e01f6809404bd420d714ccb9e8bfaf4
[25] A. Wang et al., “Genetic and Environmental Correlation Analysis of Serum Creatinine Levels in Chinese Twins,” Twin Res. Hum. Genet., vol. 26, no. 3, pp. 219–222, 2023, doi: 10.1017/thg.2023.20.
[26] Sugiyono, Metode Penelitian Kuantitatif, Kualitatif, dan R&D. ALFABETA, 2023. [Online]. Available: http://scioteca.caf.com/bitstream/handle/123456789/1091/RED2017-Eng-8ene.pdf?sequence=12&isAllowed=y
